Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 831

1.

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.

Kavanaugh A, Papp K, Gottlieb AB, de Jong EMGJ, Chakravarty SD, Kafka S, Langholff W, Farahi K, Srivastava B, Scher JU.

BMC Rheumatol. 2018 Sep 29;2:29. doi: 10.1186/s41927-018-0034-7. eCollection 2018.

2.

North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brasasard A, Burkhart C, Crowell K, Eisen D, Gottlieb A, Hamzavi I, Hazen P, Jaleel T, Kimball A, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Mar 11. pii: S0190-9622(19)30367-6. doi: 10.1016/j.jaad.2019.02.067. [Epub ahead of print]

PMID:
30872156
3.

North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brasasard A, Burkhart C, Crowell K, Eisen D, Gottlieb A, Hamzavi I, Hazen P, Jaleel T, Kimball A, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Mar 11. pii: S0190-9622(19)30368-8. doi: 10.1016/j.jaad.2019.02.068. [Epub ahead of print]

PMID:
30872149
4.

Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Secukinumab, an anti IL17A monoclonal antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa.

Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R, Alomran A, Zancanaro P, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D.

Br J Dermatol. 2019 Feb 22. doi: 10.1111/bjd.17822. [Epub ahead of print]

PMID:
30801662
5.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

PMID:
30772098
6.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

PMID:
30772097
7.

Interrater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.

Thorlacius L, Garg A, Riis PT, Nielsen SM, Bettoli V, Ingram JR, Del Marmol V, Matusiak L, Pascual JC, Revuz J, Sartorius K, Tzellos T, van der Zee HH, Zouboulis CC, Saunte DM, Gottlieb AB, Christensen R, Jemec GBE.

Br J Dermatol. 2019 Feb 6. doi: 10.1111/bjd.17716. [Epub ahead of print]

PMID:
30724351
8.

Moving the Needle on Gender Equity: a Call for Personal and Organizational Action.

Bates CK, Gottlieb AS.

J Gen Intern Med. 2019 Mar;34(3):329-330. doi: 10.1007/s11606-018-4798-7. No abstract available.

PMID:
30604127
9.

The Effect of Multiple Types of Intimate Partner Violence on Maternal Criminal Justice Involvement.

Gottlieb A, Mahabir M.

J Interpers Violence. 2019 Jan 2:886260518820705. doi: 10.1177/0886260518820705. [Epub ahead of print]

PMID:
30600751
10.

Rapidly Enlarging Malignant Proliferating Trichilemmal Tumor in a Young Female

Weiffenbach A, Katz K, Rupley K, Carter A, Gottlieb A, Shulman K.

J Drugs Dermatol. 2018 Dec 1;17(12):1325-1327.

PMID:
30586266
11.

Improving Health Literacy and Treatment Understanding of Hidradenitis Suppurativa using Group Educational Interventions.

Prussick L, Tonelli S, Gottlieb AB, Joshipura D, Alomran A, Zancanaro P, Kachuk C, Dumont N, Rosmarin D.

J Dermatolog Treat. 2018 Dec 22:1-16. doi: 10.1080/09546634.2018.1562536. [Epub ahead of print]

PMID:
30582391
12.

Clinical Goals and Barriers to Effective Psoriasis Care.

Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB.

Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18. doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.

13.

Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.

Gottlieb A, Mosthael W, Sowa JP, Canbay A.

Digestion. 2018 Dec 7:1-7. doi: 10.1159/000493259. [Epub ahead of print]

14.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30.

PMID:
30499259
15.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.

PMID:
30499246
16.

Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe.

Gottlieb A, Gratacos J, Dikranian A, van Tubergen A, Fallon L, Emir B, Aikman L, Smith T, Chen L.

Rheumatol Int. 2019 Jan;39(1):121-130. doi: 10.1007/s00296-018-4195-x. Epub 2018 Nov 13.

17.

Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.

Yosipovitch G, Foley P, Ryan C, Cather JC, Meeuwis KA, Burge R, Bleakman AP, Lin CY, Malatestinic W, Gottlieb A.

J Sex Med. 2018 Nov;15(11):1645-1652. doi: 10.1016/j.jsxm.2018.09.004.

18.

Bimekizumab for the treatment of psoriatic disease.

Natsis NE, Gottlieb AB.

Expert Opin Biol Ther. 2018 Dec;18(12):1193-1197. doi: 10.1080/14712598.2018.1538351. Epub 2018 Oct 23.

PMID:
30332893
19.

Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.

Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A.

J Rheumatol. 2019 Feb;46(2):160-165. doi: 10.3899/jrheum.180249. Epub 2018 Oct 15.

PMID:
30323006
20.
21.

Job Negotiations in Academic Medicine: Building a Competency-Based Roadmap for Residents and Fellows.

Berman RA, Gottlieb AS.

J Gen Intern Med. 2019 Jan;34(1):146-149. doi: 10.1007/s11606-018-4632-2. Epub 2018 Oct 1.

PMID:
30276658
22.

A provider global assessment quality measure for clinical practice for inflammatory skin disorders.

Gottlieb A, Salame N, Armstrong AW, Merola JF, Parra S, Takeshita J, Chen SC, Latella J, Van Beek M; International Dermatology Outcome Measures and the American Academy of Dermatology.

J Am Acad Dermatol. 2019 Mar;80(3):823-828. doi: 10.1016/j.jaad.2018.09.017. Epub 2018 Sep 20.

PMID:
30244058
23.

Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552. doi: 10.1111/jdv.15258. Epub 2018 Oct 14.

PMID:
30242918
24.

How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.

Gottlieb A, Kottmann M, Manka P, Bedreli S, Hadem J, Bechmann L, Sowa JP, Gerken G, Canbay A.

Dig Dis. 2019;37(2):147-154. doi: 10.1159/000492869. Epub 2018 Sep 18.

PMID:
30227404
25.

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.

Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ.

Clin Rheumatol. 2018 Dec;37(12):3285-3296. doi: 10.1007/s10067-018-4227-7. Epub 2018 Sep 6. Erratum in: Clin Rheumatol. 2018 Oct 11;:.

PMID:
30191421
26.

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.

Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10.

PMID:
30188571
27.

Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative.

Perez-Chada LM, Cohen JM, Gottlieb AB, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF.

Arch Dermatol Res. 2018 Nov;310(9):701-710. doi: 10.1007/s00403-018-1855-3. Epub 2018 Aug 25.

PMID:
30167814
28.

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.

Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):367-378. doi: 10.1002/acr.23738. Epub 2019 Feb 12.

PMID:
30156760
29.

Personality, environmental stressors, and diarrhea in Rhesus macaques: An interactionist perspective.

Gottlieb DH, Del Rosso L, Sheikhi F, Gottlieb A, McCowan B, Capitanio JP.

Am J Primatol. 2018 Dec;80(12):e22908. doi: 10.1002/ajp.22908. Epub 2018 Aug 28.

PMID:
30152539
30.

Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis.

Salame N, Perez-Chada LM, Singh S, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Dermatology. 2018;234(5-6):157-165. doi: 10.1159/000490413. Epub 2018 Aug 17.

31.

Reducing the Incidence of Substance Use Disorders in Anesthesiology Residents: 13 Years of Comprehensive Urine Drug Screening.

Fitzsimons MG, Baker K, Malhotra R, Gottlieb A, Lowenstein E, Zapol WM.

Anesthesiology. 2018 Oct;129(4):821-828. doi: 10.1097/ALN.0000000000002348.

PMID:
30020101
32.

Bringing the Real World Into Developmental Science: A Commentary on Weber, Fernald, and Diop (2017).

Morelli G, Bard K, Chaudhary N, Gottlieb A, Keller H, Murray M, Quinn N, Rosabal-Coto M, Scheidecker G, Takada A, Vicedo M.

Child Dev. 2018 Nov;89(6):e594-e603. doi: 10.1111/cdev.13115. Epub 2018 Jul 10.

PMID:
29989148
33.

Rationale and Models for Career Advancement Sponsorship in Academic Medicine: The Time Is Here; the Time Is Now.

Gottlieb AS, Travis EL.

Acad Med. 2018 Nov;93(11):1620-1623. doi: 10.1097/ACM.0000000000002342.

PMID:
29979207
34.

Virtual reality-based cognitive-motor training for middle-aged adults at high Alzheimer's disease risk: A randomized controlled trial.

Doniger GM, Beeri MS, Bahar-Fuchs A, Gottlieb A, Tkachov A, Kenan H, Livny A, Bahat Y, Sharon H, Ben-Gal O, Cohen M, Zeilig G, Plotnik M.

Alzheimers Dement (N Y). 2018 Mar 27;4:118-129. doi: 10.1016/j.trci.2018.02.005. eCollection 2018.

35.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Oct 1;57(10):1777-1788. doi: 10.1093/rheumatology/key161.

36.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.

PMID:
29928910
37.

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review.

Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, Liao W, Mandelin AM 2nd, Markenson JA, Mehta N, Merola JF, Prussick R, Ryan C, Schwartzman S, Siegel EL, Van Voorhees AS, Wu JJ, Armstrong AW.

JAMA Dermatol. 2018 Aug 1;154(8):934-950. doi: 10.1001/jamadermatol.2018.1412.

PMID:
29926091
38.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group.

Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.

PMID:
29893222
39.

Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.

Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW.

JAMA Dermatol. 2018 Oct 1;154(10):1137-1144. doi: 10.1001/jamadermatol.2018.1165.

PMID:
29874367
40.

Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.

Gottlieb AB, Coates LC, van Mens LJJ, Armstrong AW, Merola JF.

J Rheumatol Suppl. 2018 Jun;94:40-43. doi: 10.3899/jrheum.180137.

PMID:
29858353
41.

Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Helliwell PS, Gladman DD, Gottlieb AB.

J Rheumatol Suppl. 2018 Jun;94:1-3. doi: 10.3899/jrheum.180129.

PMID:
29858345
42.

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.

Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group.

Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22.

PMID:
29747232
43.

The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids.

Gottlieb A, Bechmann L, Canbay A.

Ann Hepatol. 2018 May-June;17(3):340-341. doi: 10.5604/01.3001.0011.7378. Epub 2018 Apr 9.

44.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K.

J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13.

45.

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.

Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Nielsen SM, Christensen R, Garg A, Jemec GBE; HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).

Br J Dermatol. 2018 Sep;179(3):642-650. doi: 10.1111/bjd.16672. Epub 2018 Jul 5.

46.

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.

J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10. doi: 10.1016/j.jaad.2018.03.037. Epub 2018 Mar 30.

47.

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.

Merola JF, Amato DA, See K, Burge R, Mallinckrodt C, Ojeh CK, Gottlieb A.

J Invest Dermatol. 2018 Sep;138(9):1955-1961. doi: 10.1016/j.jid.2018.01.041. Epub 2018 Mar 22.

PMID:
29577919
48.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

Gottlieb AB, Papp KA, Birbara CA, Shuler CL, Burge R, Erickson J, Kerr L, Mease PJ.

J Am Acad Dermatol. 2018 Sep;79(3):593-595. doi: 10.1016/j.jaad.2018.03.008. Epub 2018 Mar 17. No abstract available.

PMID:
29559395
49.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

50.

Fall incidence and associated risk factors among people with a lower limb amputation during various stages of recovery - a systematic review.

Steinberg N, Gottlieb A, Siev-Ner I, Plotnik M.

Disabil Rehabil. 2018 Mar 14:1-10. doi: 10.1080/09638288.2018.1449258. [Epub ahead of print]

PMID:
29540083

Supplemental Content

Loading ...
Support Center